Zebrafish Developmental Toxicity Evaluation Service - Creative Biogene Zebrafish Platform

Assess Developmental Toxicity with Vertebrate Relevance at Zebrafish Speed

Identifying developmental toxicity risks early in drug and chemical development is critical to avoid costly late-stage failures. Regulatory guidelines such as ICH S5(R3) for human drugs and VICH GL43 for veterinary products require developmental and reproductive toxicity studies before clinical or market phases. Traditional mammalian models, though accepted, are time-consuming, costly, and resource-intensive.

Our zebrafish-based developmental toxicity evaluation provides a high-throughput, vertebrate whole-organism platform that bridges the gap between in vitro assays and regulatory mammalian studies. Using automated deep-learning phenotyping of 17 morphological endpoints, we deliver objective, quantitative data on teratogenic potential—helping you de-risk candidates earlier and optimize your preclinical pipeline.

The service is aligned with ICH S5(R3) and VICH GL43 guidelines, supporting seamless integration into your regulatory submission package. By combining the 3R principles with predictive accuracy, we offer a practical alternative to traditional animal testing without sacrificing biological complexity.

Up to 80% predictability for human developmental toxicity Zebrafish-based teratogenicity screening has demonstrated sensitivity, specificity, and accuracy comparable to or exceeding rodent models in published validation studies.

Why Choose Our Zebrafish Developmental Toxicity Service

Predictivity

Human-Relevant Predictivity

Our validated zebrafish assay predicts human developmental toxicity with high sensitivity and specificity, often exceeding rodent models in inter-species correlation. Published evidence demonstrates >80% predictability for teratogens and non-teratogens.

Throughput

High-Throughput Automated Platform

Automated embryo handling, high-content imaging, and deep-learning-based phenotype extraction enable screening of large compound libraries with objective, quantitative readouts—reducing time and resource burden.

Regulatory

ICH/VICH-Aligned Assay Design

Our exposure window (6–120 hpf) and endpoint set are designed to address the embryo-fetal toxicity evaluation requirements of ICH S5(R3) and VICH GL43, facilitating regulatory acceptance.

How the Zebrafish Developmental Toxicity Assay Works

Solubility and Dose-Range Finding

Before definitive testing, we perform a solubility test to ensure compound stability at intended concentrations. A dose-range finding experiment (6–120 hpf exposure) determines the benchmark dose (BMD) and mortality thresholds, defining safe working concentrations for the main study.

Developmental Toxicity Test

Zebrafish embryos are exposed to five concentrations of the test compound from 6 to 120 hours post-fertilization (hpf). Mortality is recorded at 24 and 120 hpf to calculate LC50. Automated high-content imaging captures 17 morphological parameters—including body axis, heart, brain, eye, jaw, somites, and fin deformities.

Deep-Learning Phenotype Extraction

A validated deep-learning algorithm classifies each larva for qualitative phenotypes (present/absent) and extracts quantitative values. This eliminates subjective scoring and provides objective data for potency ranking.

Teratogenic Index Calculation

The most sensitive teratogenic endpoint is used to calculate EC50. The Teratogenic Index (TI = LC50/EC50) indicates teratogenic potential: higher TI values indicate greater specificity for developmental toxicity over general lethality.

Benchmark Dose Modeling and Report

Using concentration-effect curves, we derive benchmark doses (BMD) for mortality and teratogenicity. A final report includes LC50, EC50, TI, phenotypic toxicity profile, and representative images, presented in a format suitable for regulatory submissions.

Developmental Toxicity Endpoint Coverage

Our assay evaluates 17 morphological parameters covering major organ systems and developmental processes.

♥

Cardiovascular

Heart morphology, circulation, pericardial edema

▣

Craniofacial

Jaw development, eye size and position, head shape

⌬

Neural Tube

Brain morphology, neural tube closure, spinal curvature

⬢

Axial Skeleton

Somite segmentation, body axis curvature, tail fin morphology

◇

Visceral Organs

Liver, gut, yolk sac edema, swim bladder inflation

◐

Growth & Development

Body length, developmental stage, hatching rate

⚇

Pigmentation

Melanophore distribution, pigmentation pattern

⚛

Locomotor Behavior

Spontaneous movement, touch response (indicative of neuromuscular integrity)

How Zebrafish Compares to Other Developmental Toxicity Models

Feature	Zebrafish	Mouse / Rat	Cell-Based Assay	Organoid
Whole-organism complexity	Yes (vertebrate, organ systems)	Yes (mammalian)	Partial (2D/3D culture, limited tissue interaction)	Partial (organ-specific, no systemic metabolism)
Throughput (compounds per week)	High (automated, multiwell)	Low (labor-intensive, surgical)	High (96/384-well compatible)	Medium (variability, manual handling)
Ethical & 3R compliance	Larval stages exempt from animal regulation in many regions	High animal numbers, regulatory oversight	No animal use	Requires animal-derived matrices, limited animal use
Cost per compound	Low-to-medium	Very high	Low	Medium-to-high
Regulatory acceptance	Accepted as supporting evidence, aligned with ICH/VICH guidelines	Gold standard	Not standalone, used for screening	Emerging, not yet accepted
Morphological endpoint detail	17 automated phenotypes with AI	Invasive, requires dissection	Limited to cell viability, differentiation markers	Organ-level morphology, limited standardization
Timeline for study completion	10–14 weeks	6–12 months	2–4 weeks	4–8 weeks

Our Streamlined Workflow

From compound receipt to regulatory-ready report in three straightforward steps.

1

Solubility Assessment & Dose-Range Finding

We first confirm compound solubility in the exposure medium. A range-finding experiment (6–120 hpf, 5 concentrations) identifies mortality thresholds and calculates benchmark doses, ensuring that the definitive test uses non-lethal concentrations for morphology assessment.

Zebrafish embryos in 96-well plate after compound addition.

→

2

Developmental Toxicity Test & Automated Imaging

Embryos are exposed to five concentrations (triplicate) from 6–120 hpf. Daily mortality checks and high-content imaging at 120 hpf capture brightfield images for 17 morphological parameters. Deep-learning algorithms automatically detect and quantify all phenotypes.

Representative images of control (normal) and treated larvae showing developmental defects.

→

3

Data Analysis & Final Report

LC50 and EC50 are calculated from mortality and most sensitive phenotype curves. Teratogenic Index (TI) is derived. A comprehensive report includes concentration-effect graphs, phenotypic profiles, benchmark dose modeling, and regulatory summary aligned with ICH S5(R3).

Concentration-effect curves for mortality and teratogenicity.

Bioinformatics & Data Analysis Pipeline

Image analysis and statistical modeling pipeline for robust, objective endpoint quantification.

Data Processing Pipeline

Image Acquisition & Preprocessing — High-content brightfield images are captured at standardized magnification and illumination. Automated tiling and stitching produce consistent whole-larva images for downstream analysis.
Morphological Segmentation — A deep-learning-based segmentation model (U-Net architecture) identifies key anatomical structures: head, trunk, tail, heart, yolk, eye, and swim bladder. Each structure is measured for area, shape, and intensity features.
Phenotype Classification — A second deep-learning classifier (trained on annotated larvae) assigns each larva a binary positive/negative label for 17 phenotypes (e.g., bent axis, pericardial edema, reduced head size). Quantitative features such as body length and eye area are extracted.
Concentration-Response Modeling — Dose-response curves for each endpoint are fitted using benchmark dose (BMD) methodology. LC50 (mortality) and EC50 (most sensitive teratogenic endpoint) are calculated. The Teratogenic Index is derived as LC50/EC50.
Report Generation — Automated report generation compiles all results into a structured PDF with graphical summaries, phenotypic toxicity profile, and regulatory alignment statements. Raw data are provided as supplementary files.

Toxicity Metrics

Quantitative Toxicity Endpoints

LC50 (Lethal Concentration 50%) at 120 hpf
EC50 (Effective Concentration 50%) for the most sensitive teratogenic endpoint
Teratogenic Index (TI) for potency ranking
Benchmark Dose (BMD) for mortality and teratogenicity

Phenotypic Profile

Phenotypic Toxicity Profile

Occurrence of each of 17 morphological abnormalities (binary per larva)
Quantitative measurements (body length, eye area, heart rate if applicable)
Overall severity score (number of phenotypes affected per compound)
Representative images of control and treated larvae

Applications in Drug Discovery and Chemical Safety

Our zebrafish developmental toxicity assay supports a wide range of sectors.

1

Pharmaceutical Development

Screen drug candidates early in preclinical development to identify teratogenic liabilities before advancing to mammalian studies. The assay supports compound prioritization and lead optimization, aligning with ICH S5(R3) requirements for embryo-fetal toxicity evaluation.

2

Industrial Chemical Registration (REACH)

For REACH registration in the EU, developmental toxicity data are required for chemicals produced above 10 tonnes/year. Our zebrafish assay provides a NAM-based alternative to mammalian testing, generating robust hazard data for submission dossiers.

3

Environmental Contaminant Risk Assessment

Assess the developmental toxicity of environmental pollutants, such as pesticides, plasticizers, and heavy metals. The assay can be adapted for complex mixtures and field-collected samples, delivering hazard data for regulatory and ecological risk assessment.

4

Agrochemical Safety Evaluation

Evaluate the teratogenic potential of agrochemical active ingredients and formulations. The zebrafish model is well-suited for screening large numbers of candidates and can serve as a weight-of-evidence tier in a tiered testing strategy.

5

Pharmacokinetic & Metabolism Interaction Studies

Combine developmental toxicity testing with metabolomics or transcriptomics to elucidate mechanisms of teratogenicity. Our platform can be extended to include multi-omics integration for deeper mechanistic insights.

Sample Requirements and Turnaround

Standard parameters for a zebrafish developmental toxicity study.

Project Type	Material Required	Amount Required	Turnaround Time
Developmental Toxicity Screening (single compound)	Test compound (powder or concentrated solution)	10-50 mg (or 100 µL of 10 mM stock)	10–14 weeks
Dose-Range Finding (DRF) only	Test compound (powder or solution)	5-10 mg (or 50 µL of 10 mM stock)	4–6 weeks
Multi-compound library (up to 20 compounds)	Each compound as above	10-50 mg each	Project-specific; typically 12–16 weeks
Mixture or formulation testing	Concentrated stock or formulation	Volume sufficient for target concentrations (confirm with customer service)	Project-specific

Deliverables

What you receive at study completion.

Final study report in PDF format, including experimental design, methods, and results summary

LC50 and EC50 values with 95% confidence intervals

Teratogenic Index (TI) and potency classification

Phenotypic toxicity profile: list of 17 endpoints with per-concentration occurrence and severity

Concentration-effect curves for mortality and most sensitive teratogenic endpoint

Benchmark dose (BMD) modeling output

Representative high-resolution images of control and treated larvae

Raw data files (imaging metadata, endpoint scores) in Excel or CSV format

Regulatory alignment statement referencing ICH S5(R3) and VICH GL43 guidelines (if requested)

Frequently Asked Questions

How does this zebrafish assay differ from the OECD 236 Fish Embryo Acute Toxicity (FET) test?

OECD 236 assesses acute lethality over 96 hours with mortality as the sole endpoint. Our developmental toxicity assay extends exposure to 120 hpf and scores 17 morphological phenotypes using automated deep-learning. It provides mechanistic information on teratogenicity, not just survival, and is aligned with regulatory guidelines.

What is the Teratogenic Index and how is it interpreted?

The Teratogenic Index (TI) is the ratio of LC50 (lethal concentration for 50%) to EC50 (effective concentration for the most sensitive teratogenic endpoint). A TI >1 indicates that developmental toxicity occurs at concentrations below those causing general lethality, suggesting specific teratogenic potential. Higher TI values indicate stronger teratogenic specificity.

Can you test mixtures, formulations, or poorly soluble compounds?

Yes. We conduct a preliminary solubility test in the exposure medium. For poorly soluble compounds, we explore solvent vehicles (e.g., DMSO ≤0.1% final) and can adapt the protocol if the compound forms stable suspensions. Mixtures and formulations are tested as provided, with appropriate controls for each vehicle.

What is the developmental window covered by the assay?

Exposure from 6 to 120 hours post-fertilization (hpf) covers major organogenesis events: neurulation, somitogenesis, heart looping, liver and kidney development, and thyroid gland functional maturation. By 120 hpf, all digestive and metabolic organs are physiologically mature, allowing assessment of systemic developmental effects.

Do you provide data suitable for regulatory submission dossiers?

Yes. Our final report includes study design, raw data, statistical modeling (BMD, LC50, EC50, TI), and phenotypic analysis with representative images. We can also provide a regulatory alignment summary referencing ICH S5(R3) or VICH GL43, and the data format can be tailored to the requirements of your target regulatory agency.

How many compounds can be screened in a single study?

Our automated platform can screen up to 5 compounds per run (with 5 concentrations each, in triplicate). For larger libraries, we can design a matrix using dose-range finding data to reduce material needs. Throughput can be scaled based on project needs; please consult our team for feasibility assessments.